Cancer Discovery publication applies TIMING to show increased serial killing by novel CAR NK therapy
CAR27 NK cells with CD28-based costimulation resulted in significantly better long-term cytotoxicity, polyfunctionality, and survival in animals
HOUSTON, Texas — October 21, 2024. CellChorus®, the dynamic single-cell analysis company™, announced that authors from the University of Texas MD Anderson Cancer Center, the University of Houston, the Technical University of Munich, Baylor College of Medicine, the University of Nebraska Medical Center at Omaha, and CellChorus published data in Cancer Discovery describing the design of a novel CAR27 NK therapy with CD28 costimulation for patients with CD70+ hematologic malignancies and solid cancers. The CellChorus TIMING platform can directly measure serial killing—the ability of a natural killer (NK) cell to kill more than one target cancer cell—at the single-cell level. In the published research, the TIMING™ platform quantified the difference in serial killing between the CARs harboring varying intracellular domains. Approximately three times more NK cells were able to kill more than one target cancer cell when the best intracellular domain was used, as shown below.
